High-yield points
- Epidemiology: 0.67 per 100,000 per year, mostly neonates. Seizures and venous infarcts predict poor outcome .
- Hemorrhage is not a contraindication: anticoagulate even with congestive hemorrhage .
- Prefer UFH when bleeding risk is high.
- Untreated thrombi propagate in about a third of children .
- Rivaroxaban is an option after initial heparin (EINSTEIN-Jr CVT) .
- Thrombolysis and EVT: not routine.
- Evidence: TO-ACT (adults) showed no benefit.
- Role: rescue for deterioration despite anticoagulation .
- Decompressive craniectomy for herniating unilateral lesions is lifesaving, with good outcomes even in comatose adults .
- Infection-related CSVT: antibiotics, source surgery and anticoagulation, with a brief perioperative pause .
Landmark papers
- Canadian registry (deVeber et al., N Engl J Med 2001): 160 children. The incidence was 0.67 per 100,000 children per year, with neonates most often affected .
- EINSTEIN-Jr CVT (Connor et al., Blood Adv 2020): 114 children randomized 2:1 to rivaroxaban or standard anticoagulation. Recurrent VTE occurred in 0 of 73 vs 1 of 41 .
- ASH/ISTH 2024 guideline (Monagle et al., Blood Adv 2025): suggests anticoagulation over no anticoagulation for CSVT with or without hemorrhage secondary to venous congestion (conditional; very low certainty) .
Cerebral sinovenous thrombosis (CSVT) is thrombosis of the dural venous sinuses, the cortical veins or the deep venous system.
- Who gets it: it affects neonates most, then children with head and neck infection, acute illness, dehydration, or prothrombotic states.
- What it causes: venous congestion, venous infarcts with hemorrhage, and raised intracranial pressure (ICP).
- The neurosurgeon's role:
- recognizing it, including after trauma or surgery near a sinus;
- treating the source, for example otomastoiditis;
- decompression for herniation;
- selecting the rare child for endovascular rescue.
- Anticoagulation is first-line, even with hemorrhage from venous congestion .
Epidemiology and presentation
- Canadian registry (160 children) :
- Incidence: 0.67 per 100,000 children per year; neonates were most often affected.
- Presentation: seizures in 58%, diffuse neurologic signs in 76% and focal signs in 42%.
- Risk factors:
- head and neck disorders, 29%;
- acute systemic illness, 54%;
- chronic systemic disease, 36%;
- prothrombotic states, 41%.
- Venous infarcts: 41%.
- Outcome: neurologic deficits in 38% and death in 8%.
- Poor-outcome predictors: seizures at presentation and venous infarcts.
- US Kids' Inpatient Database (3,202 discharges) :
- Age: U-shaped distribution, with peaks under 4 years and at 18–20 years.
- Associated stroke: 19.3% had hemorrhagic or ischemic stroke.
- Mechanical ventilation: 25.2%, mostly neonates and young children; it carried higher mortality (OR 16.6).
- In-hospital mortality: 4.1%.
- Infection-related CSVT (74 children in EINSTEIN-Jr) :
- Otomastoiditis: 80%.
- Surgery: 55% had an operation for the infection.
Diagnosis
- Imaging: MRI with MR venography, or CT with CT venography .
- Suspect it in:
- a child with headache and papilledema or "idiopathic" intracranial hypertension;
- seizures with hemorrhagic or non-arterial infarcts;
- mastoiditis with neurologic signs;
- head injury or a fracture crossing a sinus;
- a dehydrated or septic neonate.
- Workup: look for the source (ear, sinuses, infection, dehydration, nephrotic syndrome, malignancy and asparaginase, catheters) and consider prothrombotic testing (see caveats).
Anticoagulation (first-line)
- ASH/ISTH 2024 pediatric VTE guideline :
- Recommendation 5: suggests anticoagulation over no anticoagulation for CSVT with or without hemorrhage secondary to venous congestion (conditional; very low certainty).
- Intent: bleeding from venous congestion or venous infarction is an indication for, not a contraindication to, anticoagulation. The panel stresses distinguishing it from hemorrhage of another cause.
- High bleeding risk: for CSVT with congestive hemorrhage, or around invasive procedures, consider short-half-life unfractionated heparin (UFH) rather than LMWH or DOACs.
- Duration: the guideline suggests 6 weeks rather than 3 months for select provoked VTE. Exclusions include persistent occlusive thrombus at 6 weeks and ongoing risk factors.
- Evidence base: in pooled pediatric data, partial or complete resolution occurred in 78% with vs. 53.5% without anticoagulation (RR 1.5).
- History: the ASH 2018 guideline made a strong recommendation for anticoagulation in CSVT without hemorrhage, and a conditional one with hemorrhage .
- Untreated thrombi propagate (Toronto prospective cohort, 162 patients) :
- Propagation without vs. with anticoagulation:
- neonates: 28% vs. 4%;
- children: 37% vs. 7%.
- Consequences: propagation caused new venous infarcts in 10% of neonates and 40% of children.
- Bleeding: major hemorrhage on anticoagulation was 6%, all nonfatal.
- 14% if hemorrhage was present before treatment;
- 2% if not.
- DOACs (EINSTEIN-Jr CVT, 114 children randomized 2:1) :
- Design: rivaroxaban vs. standard anticoagulation after initial heparin.
- Recurrence: recurrent VTE in 0 of 73 vs. 1 of 41.
- Clinically relevant bleeding: 6.8%, all nonmajor and noncerebral, vs. 2.5% (one subdural).
- Recanalization: complete or partial recanalization was similar between arms.
- With otomastoiditis or sinus surgery :
- Management: anticoagulate and operate.
- Perioperative course: anticoagulation was paused 0–1 day before surgery and restarted a median of 1 day after. One child (1%) had recurrent thrombosis and one (1%) major bleeding, neither related to surgery.
Thrombolysis and endovascular therapy
- Guideline position: ASH/ISTH suggests anticoagulation alone rather than thrombolysis followed by anticoagulation (recommendation 6; conditional, very low certainty) .
- When to consider it: thrombolysis "may be considered" for neurologic deterioration despite anticoagulation, depending on local resources and experience.
- Adult guidelines likewise reserve it for deterioration or thrombus progression despite anticoagulation .
- The only randomized trial was negative (TO-ACT, 67 adults with severe CVT) :
- Intervention: endovascular treatment (EVT) by mechanical thrombectomy and/or local alteplase or urokinase, plus standard care.
- Good outcome (mRS 0–1 at 12 months): 67% vs. 68%; the trial was stopped for futility.
- Mortality: 12% vs. 3%, not significant.
- Pediatric endovascular series (45 children, mean age 14.8) :
- Who: 88.9% had multi-sinus thrombosis and 31.1% parenchymal hemorrhage.
- Techniques:
- thrombolysis alone, 22.2%;
- thrombectomy alone, 37.8%;
- combined, 40.0%, with individualized urokinase dosing.
- Complications: two sinus perforations and one symptomatic hemorrhage.
- Outcome: favorable at a median of 68 months.
- The authors' conclusion: EVT is a rescue option for severe disease.
- Practical rescue triggers (see caveats):
- deterioration in consciousness;
- propagation despite therapeutic anticoagulation;
- deep venous involvement with worsening edema.
Surgery for raised ICP and mass effect
- Decompressive craniectomy (adult registry plus systematic review, 69 patients) :
- Overall outcome: unfavorable (mRS 5 or death) in only 17.4%; 56.5% were independent (mRS 0–2).
- Even the sickest: 3 of 9 with bilateral fixed pupils recovered completely.
- Worse outcomes: coma (45% vs. 84% independent) and bilateral lesions (50% vs. 11% unfavorable).
- Implication: decompress early for unilateral herniating lesions.
- Children: in the International Pediatric Stroke Study, 4 of 38 craniectomies after ischemic stroke were for CSVT .
- Raised ICP without mass lesion (see caveats):
- Medical: acetazolamide and serial ophthalmology for papilledema.
- Procedural: therapeutic lumbar puncture once a mass lesion is excluded; optic nerve sheath fenestration or CSF diversion for threatened vision.
- Shunting with an occluded sinus: venous outflow obstruction reduces CSF absorption, so shunt decisions are individualized.
- Treat the source: mastoidectomy or sinus drainage for infection-related CSVT, under continued anticoagulation .
Related topics
- Arterial Ischemic Stroke in Children: arterial counterpart, including decompressive surgery.
- Skull Fractures in Children: fractures crossing a venous sinus.
- Brain Abscess in Children: another intracranial complication of ear and sinus infection.
- Subdural Hematomas in Children: venous hemorrhage in infants.
- Craniopagus Twins: separation of conjoined twins.
- Decompressive Hemicraniectomy: step-by-step procedure.
References
- deVeber G, Andrew M, Adams C, et al. Cerebral sinovenous thrombosis in children. N Engl J Med 2001;345(6):417–423. doi:10.1056/NEJM200108093450604. PMID 11496852. verified
- Proaño JS, Martinez PA, Sendi P, et al. Characteristics and outcomes of children with cerebral sinus venous thrombosis. Neurocrit Care 2023;39(2):331–338. doi:10.1007/s12028-023-01765-7. PMID 37438549. verified
- Monagle P, Azzam M, Bercovitz R, et al. American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients. Blood Adv 2025;9(10):2587–2636. doi:10.1182/bloodadvances.2024015328. PMID 40423983. verified
- Monagle P, Cuello CA, Augustine C, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. Blood Adv 2018;2(22):3292–3316. doi:10.1182/bloodadvances.2018024786. PMID 30482766. verified
- Moharir MD, Shroff M, Stephens D, et al. Anticoagulants in pediatric cerebral sinovenous thrombosis: a safety and outcome study. Ann Neurol 2010;67(5):590–599. doi:10.1002/ana.21936. PMID 20437556. verified
- Connor P, Sánchez van Kammen M, Lensing AWA, et al. Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT). Blood Adv 2020;4(24):6250–6258. doi:10.1182/bloodadvances.2020003244. PMID 33351120. verified
- Sánchez van Kammen M, Male C, Connor P, et al. Anticoagulant treatment for pediatric infection-related cerebral venous thrombosis. Pediatr Neurol 2022;128:20–24. doi:10.1016/j.pediatrneurol.2021.12.011. PMID 35032886. verified
- Coutinho JM, Zuurbier SM, Bousser MG, et al. Effect of endovascular treatment with medical management vs standard care on severe cerebral venous thrombosis: the TO-ACT randomized clinical trial. JAMA Neurol 2020;77(8):966–973. doi:10.1001/jamaneurol.2020.1022. PMID 32421159. verified
- Li J, Wang C, Liu K, et al. Safety and efficacy of endovascular treatment in symptomatic pediatric cerebral venous sinus thrombosis. Neuroradiology 2026 (online ahead of print). doi:10.1007/s00234-026-04196-1. PMID 42825816. verified
- Saposnik G, Bushnell C, Coutinho JM, et al. Diagnosis and management of cerebral venous thrombosis: a scientific statement from the American Heart Association. Stroke 2024;55(3):e77–e90. doi:10.1161/STR.0000000000000456. PMID 38284265. verified
- Ferro JM, Crassard I, Coutinho JM, et al. Decompressive surgery in cerebrovenous thrombosis: a multicenter registry and a systematic review of individual patient data. Stroke 2011;42(10):2825–2831. doi:10.1161/STROKEAHA.111.615393. PMID 21799156. verified
- Lehman LL, deVeber G, Pergami P, et al. Characteristics and outcome in children with craniectomy following acute ischemic stroke in the International Pediatric Stroke Study. J Child Neurol 2019;34(12):765–769. doi:10.1177/0883073819855534. PMID 31282248. verified
Verification (2026-11-17):
- Each reference's authors, title, journal, year, volume, pages, DOI and PMID were checked on PubMed. Numbers were checked against the PubMed abstracts.
- The ASH/ISTH 2024 recommendations (3) were checked against the open-access full text (PMC12235321): recommendations 3, 5 and 6, the UFH good-practice statement and the pooled resolution figures. The ASH 2018 recommendation strengths (4) were checked against the PMC full text (PMC6258911).
- Reference 9 is online-first, without volume or pages.
Caveats:
- The following are standard teaching, not drawn from the cited abstracts:
- the imaging triggers for suspecting CSVT;
- the prothrombotic workup;
- the "practical rescue triggers" for EVT;
- raised-ICP management (acetazolamide, lumbar puncture, optic nerve sheath fenestration, CSF diversion).
- The decompression data (11) are from adults; pediatric craniectomy data for CSVT are very limited (12).
- TO-ACT enrolled adults only.
- The figure is an original schematic.